Actively Recruiting
Study to Evaluate Pelabresibs Effect on Drug Processing with Repaglinide, Midazolam, and Combined Oral Contraceptive in Advanced Cancer Patients
Led by Novartis Pharmaceuticals · Updated on 2026-10-09
24
Participants Needed
6
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how the drug pelabresib affects the way other drugs are processed in the body in adults with advanced cancers who have no standard treatment options left. This study aims to understand the interactions between pelabresib and three specific drug combinations repaglinide with midazolam, and a combined oral contraceptive containing drospirenone and ethinyl estradiol. The trial is phase 1b and open-label, focusing on treatment effects in this patient population. The study has two parts. In Part 1, participants are assigned to one of two groups Arm A receives pelabresib with repaglinide and midazolam, and Arm B receives pelabresib with drospirenone and ethinyl estradiol. Pelabresib is given orally at 225 mg daily for 14 days followed by a 7-day break. Participants in Arm A are hospitalized for two nights around specific dosing days, while those in Arm B may be hospitalized for up to 10 nights in total during the dosing schedule. Part 2 allows participants who benefit clinically to continue pelabresib treatment in additional cycles until the study ends or other stopping criteria are met. Participants start with a screening visit and then receive their first dose after enrollment. They undergo pharmacokinetic blood sampling over 21-day cycles to measure drug levels and interactions. Safety is monitored through adverse event reporting, and participants have an End of Treatment visit within 7 days after stopping pelabresib. A 30-day safety follow-up monitors for side effects, and those with blood cancers have additional follow-up every 3 months to check for progression to acute leukemia. Total participation duration varies depending on treatment continuation and follow-up needs.
CONDITIONS
Brief Title
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here